Angiotensin II receptors blockers in treatment of metabolic syndrome
Topicality of metabolic syndrome's (MS) problem is very high because MS related to development of cardiovascular diseases. As is well known, development of arterial hypertension (AH) in patients with MS is conditioned by activation of rennin-angiotensin-aldosterone system (RAAS). While patient has insulin resistance, blockade of RAAS is pathogenetically grounded, and it justifies administration of angiotensin receptors type I (AT1) blockers in treatment of AH in MS patients. The article describes pathophysiological mechanisms of AH forming in MS patients; it presents the data from clinical trials, showing advisability of AT1 blockers administration and its preventive effect on stroke, diabetes type II, and beneficial action on left ventricle hypertrophy and nephropathy regress.